Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week (DDW) Annual Meeting 2016-05-24 00:56
More than 96 Percent of Claimants Opt-In to ACTOS Resolution Program; Takeda Expects Resolution to Become Effective Once Submission Review Completed; Takeda Stands Behind ACTOS 2015-09-14 09:49
Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2015-07-30 22:58
Takeda Regroups Singapore Operations in New, Expanded Office 2015-02-25 10:00
Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting 2014-12-09 09:30
Takeda Presents Phase 2 Data on Maintenance with Single-Agent Investigational Ixazomib in Patients with Newly Diagnosed Multiple Myeloma 2014-12-09 09:30
Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS(R) (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting 2014-12-09 09:30
Takeda's Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by U.S. FDA for Relapsed or Refractory Systemic Light-chain Amyloidosis 2014-12-05 09:30
1 2